Any current/future new fundraising through debt or equity?

The document does not explicitly mention any current or planned fundraising through debt or equity. The company has a well-capitalized balance sheet to fund future expansion and growth plans. Capex of approximately INR 1,770 million was incurred during the nine months ended December 2023, primarily towards the Noida hospital project. The company focuses on organic growth but remains open to growth opportunities beyond organic expansions, provided they meet their strategic criteria. No specific details on issuing new debt or equity were disclosed in the provided transcript.

Future growth expectations in sales/revenue/volumes?

Strong volume-driven growth continues across both developing (Lucknow, Patna) and mature hospitals, with 13-17% growth in inpatient footfalls and occupied bed days reported recently. Developing hospitals’ revenue share has increased significantly, evidencing strong expansion momentum. Noida hospital opening by end of FY25 expected to add substantial capacity and revenue streams. Bed expansions planned: 140-150 beds in Lucknow and 30-40 beds in Patna by March 2024; 60 beds in Gurgaon repurposed for daycare oncology and 50 beds added to mother-child unit. Focus remains on balanced tariff increas

Future growth expectations in earnings/operating earnings/profits/EPS?

Medanta emphasizes long-term growth over quarterly optimization, focusing on annualized or longer-term performance. Volume growth is the primary driver of revenue, with inpatient footfalls and occupied bed days showing double-digit YoY growth. Developing hospitals (Lucknow, Patna) show strong revenue and EBITDA growth, with improving margins; Lucknow and Patna expected to add beds, fueling further growth. Noida hospital project progressing, with operations expected by FY25 end; breakeven anticipated in 3-4 years, possibly faster due to design. Margins expected to benefit from operational lever

Global HealthQ3 FY24Healthcare Services

Global Health Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,357P/E: 70.2Market Cap: ₹40.2K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Strong volume-driven growth continues across both developing (Lucknow, Patna) and mature hospitals, with 13-17% growth in inpatient footfalls and occupied bed days reported recently.
Developing hospitals’ revenue share has increased significantly, evidencing strong expansion momentum.
Noida hospital opening by end of FY25 expected to add substantial capacity and revenue streams.
Bed expansions planned: 140-150 beds in Lucknow and 30-40 beds in Patna by March 2024; 60 beds in Gurgaon repurposed for daycare oncology and 50 beds added to mother-child unit.
Focus remains on balanced tariff increases, with growth primarily driven by volumes rather than aggressive tariff hikes.
Continued addition of doctors (253 in nine months) to support volume growth and service expansion.
Opportunities being explored in UP beyond Lucknow, including Noida and potentially Eastern and Western UP, indicating longer-term growth prospects.
OPD pharmacy business also registering strong revenue growth of 28% year-on-year.

Margin guidance

Category 3

Medanta emphasizes long-term growth over quarterly optimization, focusing on annualized or longer-term performance.
Volume growth is the primary driver of revenue, with inpatient footfalls and occupied bed days showing double-digit YoY growth.
Developing hospitals (Lucknow, Patna) show strong revenue and EBITDA growth, with improving margins; Lucknow and Patna expected to add beds, fueling further growth.
Noida hospital project progressing, with operations expected by FY25 end; breakeven anticipated in 3-4 years, possibly faster due to design.
Margins expected to benefit from operational leverage as volumes increase on a fixed cost base, though input cost inflation and regulation could dilute margins.
Conservative tariff increases with focus on affordability; ARPOB growth moderate (~4% YoY), driven more by volume than price hikes.
Continued onboarding of doctors and capacity expansion expected to support sustainable volume and profit growth.

See what Global Health management said on margin guidance — free account, 30 seconds.

Fundraise plans

The document does not explicitly mention any current or planned fundraising through debt or equity.
The company has a well-capitalized balance sheet to fund future expansion and growth plans.
Capex of approximately INR 1,770 million was incurred during the nine months ended December 2023, primarily towards the Noida hospital project.
The company focuses on organic growth but remains open to growth opportunities beyond organic expansions, provided they meet their strategic criteria.
No specific details on issuing new debt or equity were disclosed in the provided transcript.

Order book

The transcript provided from Medanta – Global Health Limited's earnings call does not explicitly mention current or expected order book or pending orders. However, relevant insights related to growth plans and capacity expansions include: - Ongoing construction of the Noida hospital, expected to commence operations by end of FY25 with around 300 beds planned. - Addition of approximately 140-150 beds in Lucknow and 30-40 beds in Patna by March 2024. - Conversion of 60 beds into daycare for medical oncology chemotherapy in Gurugram and addition of around 50 beds in mother and child unit. - Incorporation of a special purpose vehicle (SPV) with DLF Limited for super-specialty hospital in South Delhi. - Management is actively exploring both organic expansion and inorganic opportunities, pending due diligence and regulatory approvals, such as for the Indore project. - No specific figures on order books or pending orders disclosed in the call or report.

See what Global Health management said on order book — free account, 30 seconds.

Capex plans

Yes

Incurred capex of approx. INR 1,770 million for nine months ended December 2023; 66% (INR 1,170 million) toward Noida hospital project.
Noida hospital construction is on track with 82% superstructure completed; mechanical, electrical, and plumbing work underway.
Noida hospital expected to commence operations by end of FY25.
Plan to add 140-150 beds in Lucknow and 30-40 beds in Patna by end of March 2024.
Conversion of a floor in Medanta Gurugram from approx. 60 beds to daycare for medical oncology chemotherapy procedures.
Adding approx. 50 beds to mother and child unit in Gurugram.
Incorporated a SPV company (GHL Hospitals Limited) with DLF Limited to construct and operate a super-specialty Medanta Hospital in South Delhi.
Actively evaluating opportunities beyond current hospitals for expansion, subject to detailed due diligence and compliance.

Track Global Health — get its next earnings analysis in your feed

How does Global Health rank vs peers in Healthcare Services?

Pro feature

ThisGlobal Health

Rev 2Mar 3

See where Global Health sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Global Health rank in Healthcare Services?

Compare Global Health against every Healthcare Services company (Q3 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Global Health's management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Suven Life Sciences Ltd (Q1 FY22)
The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…
Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →